Eliquis Lawsuit 2026: Bleeding Claims, Who Qualifies & How to File
Eliquis (apixaban) lawsuits allege that Bristol-Myers Squibb and Pfizer failed to adequately warn patients and doctors about severe, sometimes uncontrollable bleeding — including gastrointestinal bleeds, brain hemorrhages, and hemorrhagic strokes. The federal multidistrict litigation consolidated in 2017 was dismissed that same year, and as of October 2026 no Eliquis MDL remains pending and no large public settlements have been announced.
Key facts
- Eliquis is apixaban, an anticoagulant sold by Bristol-Myers Squibb and Pfizer, FDA-approved in 2012.
- Fifty-three federal suits were consolidated into one MDL in February 2017 — dismissed by Judge Denise Cote in November 2017.
- The core allegation was inadequate warnings about serious bleeding and the lack of a reversal agent.
- As of October 2026, no Eliquis MDL is pending and no large public Eliquis settlement has been announced.
- In December 2025 the FDA found that Andexxa, the reversal agent for Eliquis bleeding, carried thrombotic risks outweighing its benefits; AstraZeneca withdrew it from the U.S. market.
The Drug at the Center of the Claims
Eliquis is the brand name for apixaban, a prescription anticoagulant that slows blood clotting to reduce stroke and blood-clot risk in non-valvular atrial fibrillation. FDA-approved in 2012 on the strength of the industry-funded ARISTOTLE trial, it was marketed as warfarin's modern successor: no routine monitoring, fewer dietary restrictions, a better safety profile — claims plaintiffs would later challenge. You can watch a short explainer of how blood thinner litigation works on the Problem Solved channel.
What the Lawsuits Actually Alleged
The complaints converged on a single theme: warning. Patients and surviving families claimed Bristol-Myers Squibb and Pfizer failed to warn physicians and patients clearly enough about severe, life-threatening bleeding.
The suits alleged that the claim Eliquis was safer than warfarin lacked adequate support; that the label downplayed the practical danger, since doctors had no approved antidote for Eliquis bleeding in an emergency; and that the approval evidence was questionable, citing reported errors at a Chinese trial site that delayed FDA approval by nine months.
Named plaintiff Carmen Flores, who sued in early 2017, described a severe gastrointestinal bleed in February 2015 requiring intermittent hospitalization, followed by an ischemic stroke she attributed to the blood loss.
What Happened to the Litigation
In February 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated 53 Eliquis actions into one MDL in the Southern District of New York. A mass tort is a coordinated proceeding in which many individual lawsuits — each keeping its own case and damages — are handled together, unlike a class action, where one representative case stands for everyone (see our guide to mass torts versus class actions).
Nine months later, Judge Denise Cote dismissed the cases outright, holding that the Eliquis label adequately warns of its risks and calling the plaintiffs' arguments "unavailing" — a dismissal still shaping every Eliquis conversation.
As of October 2026, no Eliquis MDL is pending and no large public settlement has been announced. Rival blood thinners ended differently: about $650 million for Pradaxa claims in 2014 and $775 million for Xarelto claims in 2019 — settlements Eliquis cases never reached.
The Injuries the Complaints Described
The suits were never about minor bruising. The injuries named were severe gastrointestinal and internal bleeding (sometimes fatal), brain hemorrhages, hemorrhagic and ischemic strokes, spinal epidural hematomas, and wrongful-death claims by families of patients who died.
Who Can Still Qualify for a Claim
The 2017 dismissal narrowed the field but did not erase every path. A case remains worth evaluating where these conditions hold: documented Eliquis use, a serious bleeding event on the drug (gastrointestinal or internal bleed, brain hemorrhage, hemorrhagic stroke, or death), and a claim within the statute of limitations — typically two to three years, varying by state.
One candid note: as of 2026, some firms that once handled these cases publicly state they are no longer accepting new Eliquis matters — an honest evaluation will confront the 2017 dismissal head-on. Comparable warning-and-design theories have played out differently elsewhere: see the Ozempic litigation of 2026 and the ParaGard IUD litigation.
How to File: The Practical Path
With no active MDL, a new Eliquis case would be filed individually. The sequence looks like this.
Gather your records first. Prescription history, hospital records of the bleeding event, discharge summaries — and an autopsy report in a death case.
Request a case review. Most product-liability firms evaluate drug cases on a free consultation and work on contingency. Ask directly whether the firm is currently taking Eliquis cases and what theory distinguishes your facts from the dismissed 2017 claims.
Act before the deadline. These clocks run quickly and silently, so a prompt review protects your rights.
The Reversal-Agent Twist of 2025
One allegation — that Eliquis launched with no way to stop its bleeding — was partly answered by Andexxa, the reversal agent for factor-Xa inhibitors. In December 2025, that answer vanished: the FDA found it carried thrombotic risks outweighing its benefits, and AstraZeneca withdrew it from the U.S. market. The withdrawal does not resurrect the dismissed 2017 cases, but it renewed attention on Eliquis bleeding risk.
A Realistic Word on Compensation
There is no public Eliquis settlement to report. Compensation varies widely by case, and because most settlements are confidential, no reliable public per-case figures exist for Eliquis. Medical bills, lost income, pain and suffering, and wrongful-death damages are the standard categories, and every figure depends on the facts.
This article is general information, not legal advice; if you believe Eliquis harmed you or a family member, consult a qualified attorney about your situation.
Who Benefits From This — and Who Does Not
Eliquis (apixaban) lawsuits allege that Bristol-Myers Squibb and Pfizer failed to adequately warn patients and doctors about severe, sometimes uncontrollable bleeding — including gastrointestinal bleeds, brain hemorrhages, and hemorrhagic strokes. The federal multidistrict litigation consolidated in 2017 was dismissed that same year, and as of October 2026 no Eliquis MDL remains pending and no large public settlements have been announced. This guide helps some readers assess a claim honestly — and warns others not to expect a settlement payout.
Who benefits:
- Patients prescribed Eliquis who suffered a serious bleeding event — gastrointestinal bleeding, brain hemorrhage, or hemorrhagic stroke, within the statute of limitations: secure your medical and prescription records and request a free case review from a product-liability attorney.
- Families of a patient who died after a serious bleeding event — the same first step applies: preserve the prescription and medical records, then ask an attorney whether the claim is still within the limitations period.
- Readers who are unsure whether they have a claim at all — start with the records, not with expectations: the dismissal turned on Judge Denise Cote's holding that the label adequately warned about bleeding risks, so an attorney must assess the facts case by case.
Who does not benefit:
- Anyone expecting a settlement payout — none has been announced: unlike Pradaxa claims in 2014 (about $650 million) and Xarelto claims in 2019 (about $775 million), Eliquis cases never reached that stage.
- Patients who took Eliquis without a serious bleeding event — the complaints described serious bleeding injuries, so use without such an event does not match the claims litigated.
- Claims filed outside the statute of limitations — eligibility in the article is expressly framed within the limitations period, and a late claim fails on timing alone.
Related reading: Medtronic Bravo Capsule Recall 2026.
FAQ
Is there an Eliquis class action lawsuit in 2026?
No. The 2017 federal MDL was dismissed that same year, and as of October 2026 no Eliquis class action or active MDL exists.
Why were the Eliquis lawsuits dismissed?
Judge Denise Cote held that the Eliquis label adequately warned patients about bleeding risks and called the plaintiffs' arguments "unavailing."
Who qualifies to file an Eliquis lawsuit?
Generally, someone prescribed Eliquis who suffered a serious bleeding event — gastrointestinal bleeding, brain hemorrhage, or hemorrhagic stroke — or the family of a patient who died, within the statute of limitations.
Has there been an Eliquis settlement?
None has been announced. Rival blood thinners settled differently — about $650 million for Pradaxa claims in 2014 and $775 million for Xarelto claims in 2019 — but Eliquis cases never reached that stage.
What should I do first if I think I have a claim?
Secure your medical and prescription records and request a free case review from a product-liability attorney.
Who should not pursue an Eliquis claim?
Anyone who took Eliquis without suffering a serious bleeding event, anyone whose claim falls outside the statute of limitations, and anyone expecting a settlement payout: as of October 2026 no Eliquis MDL remains pending and no large public settlement has been announced, so there is no fund to join.